checkAd
    Startseite > Aktien > Sarepta Therapeutics > Nachrichten
    Sarepta Therapeutics Aktie
    124,20
     
    EUR
    +2,01 %
    +2,45 EUR
    Letzter Kurs 03.05.24 Tradegate
    123,60
     
    EUR
    80 STK
    Geldkurs 03.05.24
    124,80
     
    EUR
    80 STK
    Briefkurs 03.05.24
    ISIN: US8036071004 · WKN: A1J1BH · SYM: AB3A · USA

    Neueste Nachrichten

    Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
    03.05.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
    01.05.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    01.05.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
    24.04.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    29.03.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics to Present at Upcoming Investor Conferences
    04.03.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    01.03.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
    29.02.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
    28.02.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
    21.02.24 · Business Wire (engl.) · Sarepta Therapeutics
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 19.02.2024
    19.02.24 · wO Chartvergleich · AMETEK
    Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
    16.02.24 · Business Wire (engl.) · Sarepta Therapeutics